The claim
“Our curcumin is the natural ibuprofen — same effect, no side effects.”
This comparison appears in numerous social media ads and supplement product pages. In EU regulatory terms, it is particularly problematic because it positions a food supplement as a functional equivalent of a licensed non-prescription drug.
What the evidence actually shows
The most frequently cited study is the RCT by Kuptniratsaikul et al. (2014), which compared 1,500 mg/day of curcuma extract with 1,200 mg/day of ibuprofen in patients with knee osteoarthritis over four weeks. Results: comparable pain and function scores in this specific setting, with more gastrointestinal side effects in the ibuprofen arm.
Several things this study does not show:
- It does not demonstrate that any curcumin product would achieve the same result. The trial used a standardised extract; commercial supplements vary widely in curcumin content, formulation, and bioavailability.
- It does not generalise to other pain types, other populations, or longer treatment durations.
- Native curcumin has notoriously poor bioavailability. Without specific formulation strategies (piperine combination, lipid-based delivery, micellar forms), absorption is limited — which makes product-to-product comparisons unreliable.
The broader body of evidence is small and heterogeneous. Large-scale, methodologically robust trials with hard clinical endpoints are lacking.
EFSA status
No EU health claims are approved for curcuma or curcumin. Marketing statements that imply drug-equivalent anti-inflammatory or analgesic action are therefore legally high-risk under Regulation (EC) No 1924/2006.
Verdict
This claim is exaggerated. Individual studies provide interesting signals, but they do not support a blanket equivalence with ibuprofen, nor a “natural anti-inflammatory drug” narrative. A sober summary of the limited evidence base is defensible. Positioning curcumin as an interchangeable OTC drug replacement is not.